Published in J Thorac Cardiovasc Surg on July 01, 2000
Intraoperative management of tracheobronchial rupture after double-lumen tube intubation. Surg Today (2012) 1.02
Airway trauma: a review on epidemiology, mechanisms of injury, diagnosis and treatment. J Cardiothorac Surg (2014) 0.87
Tracheal laceration during intubation of a double-lumen tube and intraoperative fiberoptic bronchoscopic evaluation through an LMA in the lateral position -A case report-. Korean J Anesthesiol (2011) 0.85
Iatrogenic Left Main Bronchus Injury following Atraumatic Double Lumen Endotracheal Tube Placement. Case Rep Anesthesiol (2013) 0.83
Iatrogenic tracheobronchial rupture. J Med Life (2014) 0.78
Tracheotomy-related posterior tracheal wall rupture, trans-tracheal repair. Acta Otorhinolaryngol Ital (2007) 0.76
Does Surgical Repair Still have a Role for Iatrogenic Tracheobronchial Rupture? Clinical Analysis of a Thoracic Surgeon's Opinion. Ann Thorac Cardiovasc Surg (2016) 0.75
Management of Postintubational Tracheal Injury by Endoscopic Stent Placement: Case Report and Review of the Literature. Thorac Cardiovasc Surg Rep (2016) 0.75
Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet (1992) 3.77
Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res (1997) 1.85
Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression. J Pathol (1994) 1.65
Surgery plus adjuvant chemotherapy for T1-3N0M0 small-cell lung cancer. Rationale for current approach. Am J Clin Oncol (1991) 1.56
Results and prognostic factors of surgery in the management of non-small cell lung cancer with solitary brain metastasis. Cancer (1991) 1.56
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res (1998) 1.54
Pulmonary lipid peroxidation in cigarette smokers and lung cancer patients. Chest (1990) 1.52
Thymic carcinoma: a report of 13 cases. Eur J Surg Oncol (2001) 1.52
Most peripheral, node-negative, non-small-cell lung cancers have low proliferative rates and no intratumoral and peritumoral blood and lymphatic vessel invasion. Rationale for treatment with wedge resection alone. J Thorac Cardiovasc Surg (1992) 1.41
Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst (1997) 1.41
Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J Pathol (1996) 1.40
Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol (1995) 1.40
Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res (1997) 1.39
Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer (1995) 1.27
A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer (2002) 1.19
Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer (1995) 1.19
A pilot study of the role of TC-99 radionuclide in localization of pulmonary nodular lesions for thoracoscopic resection. Eur J Cardiothorac Surg (2000) 1.18
Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer (1991) 1.15
Gastropleural fistula as complication of postpneumonectomy empyema. J Cardiovasc Surg (Torino) (2000) 1.11
Resection of single brain metastasis in non-small-cell lung cancer: prognostic factors. J Thorac Cardiovasc Surg (1996) 1.10
Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br J Cancer (1997) 1.06
p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene (1996) 1.05
p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res (1993) 1.05
Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. Eur J Cancer (1998) 1.04
The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancer. Cancer (1992) 1.00
Long-lasting effects of tobacco smoking on pulmonary drug-metabolizing enzymes: a case-control study on lung cancer patients. Cancer Res (1988) 0.99
Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. Br J Cancer (1999) 0.98
Treatment by VATS of giant bullous emphysema: results. Eur J Cardiothorac Surg (1998) 0.97
67-Kilodalton laminin receptor expression correlates with worse prognostic indicators in non-small cell lung carcinomas. Clin Cancer Res (1997) 0.96
Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer. Clin Cancer Res (1999) 0.96
Mediastinal goitres: when the transthoracic approach? Acta Chir Belg (2001) 0.95
mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn Mol Pathol (1995) 0.95
FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and K-ras mutations. J Pathol (1998) 0.95
Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. Br J Cancer (2000) 0.94
Modulation of neoangiogenesis in bronchial preneoplastic lesions. Oncol Rep (1999) 0.93
Neoangiogenesis: a putative marker of malignancy in non-small-cell lung cancer (NSCLC) development. Int J Cancer (1996) 0.91
Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density. Clin Cancer Res (1999) 0.91
Comparison of pulmonary DNA adduct levels, measured by 32P-postlabelling and aryl hydrocarbon hydroxylase activity in lung parenchyma of smokers and ex-smokers. Carcinogenesis (1991) 0.90
Acute major airway injuries: clinical features and management. Eur J Cardiothorac Surg (2001) 0.88
Extended thymectomy in myasthenia gravis: a team-work of neurologist, thoracic surgeon and anaesthesist may improve the outcome. Eur J Cardiothorac Surg (2001) 0.87
Tumor angiogenesis and biologic markers in resected stage I NSCLC. Eur J Cardiothorac Surg (1997) 0.87
Genetic analysis of lung tumours of non-smoking subjects: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus. Br J Cancer (1998) 0.86
Thymomas: clinical-pathological correlations. J Cardiovasc Surg (Torino) (2006) 0.86
Adrenal masses in non-small cell lung carcinoma patients: is there any role for laparoscopic procedures? J Laparoendosc Adv Surg Tech A (1998) 0.86
Posterior wall laceration of the thoracic trachea: the transcervical-transtracheal approach. Eur J Cardiothorac Surg (2001) 0.86
Histone complements of human tissues, carcinomas, and carcinoma-derived cell lines. Mol Cell Biochem (1984) 0.86
The multimodality treatment of thymic carcinoma. Eur J Cardiothorac Surg (2001) 0.85
Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas. J Pathol (1997) 0.85
Surgical treatment of primary lung cancer and solitary brain metastasis. Thorax (1985) 0.85
Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer. Ann Oncol (1996) 0.84
Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer. Int J Cancer (1998) 0.84
Influence of bulla volume on postbullectomy outcome. Can Respir J (2001) 0.84
Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer. Oncogene (2001) 0.84
Surgery in the management of small cell lung cancer. Eur J Cardiothorac Surg (1997) 0.83
Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. J Thorac Cardiovasc Surg (1993) 0.82
Combined Nd-YAG laser/HDR brachytherapy versus Nd-YAG laser only in malignant central airway involvement: a prospective randomized study. Lung Cancer (2000) 0.82
Quantitation by competitive PCR assay of vascular endothelial growth factor in non-small cell lung carcinomas. Int J Oncol (1999) 0.81
Recurrence and death in non-small cell lung carcinomas: a prognostic model using pathological parameters, microvessel count, and gene protein products. Clin Cancer Res (1996) 0.81
Combination chemotherapy with vinorelbine, ifosfamide, and cisplatin: a phase II study in stage IIIB-IV non-small cell lung cancer. Semin Oncol (1994) 0.81
Second primary lung cancer and relapse: treatment and follow-up. Eur J Cardiothorac Surg (1995) 0.81
Identification of Fas (APO-1/CD95) and p53 gene mutations in non-small cell lung cancer. Int J Oncol (2002) 0.81
p53 expression in non small cell lung cancer: clinical and biological correlations. Anticancer Res (1993) 0.80
Phase II feasibility study of high dose epirubicin-based regimens for untreated patients with small-cell lung cancer. Am J Clin Oncol (1990) 0.79
[Diagnosis and treatment of pleuro-pericardial cysts. Role of videosurgery]. Minerva Chir (1999) 0.79
Energy metabolism of thoracic surgical patients in the early postoperative period. Effect of posture. Chest (1996) 0.79
Perfusion lung scan in the preoperative assessment of pulmonary function in bronchial carcinoma. J Nucl Med Allied Sci (1978) 0.79
Effects of thymostimulin on chemotherapy-induced toxicity and long-term survival in small cell lung cancer patients. Anticancer Res (1989) 0.78
Optimal treatment for T1-3NOMO small cell lung cancer: surgery plus adjuvant chemotherapy. Anticancer Res (1990) 0.78
Possible prognostic value of pulmonary AH-locus-linked enzymes in patients with tobacco-related lung cancer. Int J Cancer (1990) 0.78
Phase II study of high-dose epirubicin in untreated patients with small-cell lung cancer. Am J Clin Oncol (1990) 0.77
Glutathione conjugation with 1-chloro-2,4-dinitrobenzene (CDNB): interindividual variability in human liver, lung, kidney and intestine. Int J Clin Pharmacol Ther (1995) 0.77
Gamma probe-guided thoracoscopic surgery of small pulmonary nodules. Tumori (2000) 0.76
Penetration of clofoctol into human lung. J Antimicrob Chemother (1987) 0.76
A pharmacokinetic study of clofoctol in human plasma and lung tissue by using a microbiological assay. Drugs Exp Clin Res (1988) 0.76
Intrapleural BCG in postsurgical stage I non-small cell lung cancer. Anticancer Res (1989) 0.75
[The evaluation of the cardiotoxicity of 4'-epidoxorubicin at high doses]. Cardiologia (1991) 0.75
[The diagnosis of primary lesions of the anterior mediastinum]. Minerva Chir (1994) 0.75
Inhibition of mouse parenchymal cells proliferation by mosquito larvae extract. Cell Mol Biol (Noisy-le-grand) (1994) 0.75
Pre-operative chemotherapy for stage IIIa (N2) non-small cell lung cancer. Eur J Surg Oncol (1995) 0.75
Long-term evaluation of intrapleural bacillus Calmette-Guerin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer. Am J Clin Oncol (1991) 0.75